Cetuximab: Preclinical Evaluation of a Monoclonal Antibody Targeting EGFR for Radioimmunodiagnostic and Radioimmunotherapeutic Applications

Overview

Journal Cancer Biother Radiopharm

Specialties Oncology
Pharmacology
Radiology

Date 2008 Nov 13

PMID 18999934

Citations 36

Authors

Diane E Milenic

Karen J Wong

Kwamena E Baidoo

Geoffrey L Ray

Kayhan Garmestani

Mark Williams

Martin W Brechbiel

Affiliations

Soon will be listed here.

Abstract

The monoclonal antibody, cetuximab, binds to epidermal growth-factor receptor and thus provides an opportunity to create both imaging and therapies that target this receptor. The potential of cetuximab as a radioimmunoconjugate, using the acyclic bifunctional chelator, CHX-A"-DTPA, was investigated. The pharmacokinetic behavior in the blood was determined in mice with and without tumors. Tumor targeting and scintigraphic imaging were evaluated in mice bearing xenografts of LS-174T (colorectal), SHAW (pancreatic), SKOV3 (ovarian), DU145 (prostate), and HT-29 (colorectal). Excellent tumor targeting was observed in each of the models with peak tumor uptakes of 59.8 +/- 18.1, 22.5 +/- 4.7, 33.3 +/- 5.7, 18.2 +/- 7.8, and 41.7 +/- 10.8 injected dose per gram (%ID/g) at 48-72 hours, respectively. In contrast, the highest tumor %ID/g obtained in mice bearing melanoma (A375) xenografts was 6.3 +/- 1.1 at 72 hours. The biodistribution of (111)In-cetuximab was also evaluated in nontumor-bearing mice. The highest %ID/g was observed in the liver (9.3 +/- 1.3 at 24 hours) and the salivary glands (8.1 +/- 2.8 at 72 hours). Scintigraphy showed excellent tumor targeting at 24 hours. Blood pool was evident, as expected, but cleared over time. At 168 hours, the tumor was clearly discernible with negligible background.

Citing Articles

Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy.

Fasano M, Della Corte C, Viscardi G, Di Liello R, Paragliola F, Sparano F Ther Adv Med Oncol. 2021; 13:1758835920949418.

PMID: 33767760 PMC: 7953226. DOI: 10.1177/1758835920949418.

Zr-DFO-Cetuximab as a Molecular Imaging Agent to Identify Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma.

Benedetto R, Massicano A, Crenshaw B, Oliveira R, Reis R, Araujo E Cancer Biother Radiopharm. 2019; 34(5):288-296.

PMID: 30865493 PMC: 6588098. DOI: 10.1089/cbr.2018.2616.

Analysis of Progress and Challenges of EGFR-Targeted Molecular Imaging in Cancer With a Focus on Affibody Molecules.

Chen W, Shen B, Sun X Mol Imaging. 2019; 18:1536012118823473.

PMID: 30799684 PMC: 6348515. DOI: 10.1177/1536012118823473.

Synthesis and preclinical investigation of Tc-p-SCN-Bzl-DTPA-cetuximab for targeting EGFR using head and neck squamous cell carcinoma (HNSCC) xenografts.

Shah S, Gul-E-Raana Mol Biol Rep. 2019; 46(2):1675-1682.

PMID: 30680596 DOI: 10.1007/s11033-019-04616-x.

Biodistribution of a Radiolabeled Antibody in Mice as an Approach to Evaluating Antibody Pharmacokinetics.

Allen K, Jiao R, Malo M, Frank C, Dadachova E Pharmaceutics. 2018; 10(4).

PMID: 30563123 PMC: 6320949. DOI: 10.3390/pharmaceutics10040262.

References

Haigler H, Ash J, Singer S, Cohen S . Visualization by fluorescence of the binding and internalization of epidermal growth factor in human carcinoma cells A-431. Proc Natl Acad Sci U S A. 1978; 75(7):3317-21. PMC: 392766. DOI: 10.1073/pnas.75.7.3317. View

Fraker P, SPECK Jr J . Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun. 1978; 80(4):849-57. DOI: 10.1016/0006-291x(78)91322-0. View

Esteban J, Schlom J, Gansow O, Atcher R, Brechbiel M, Simpson D . New method for the chelation of indium-111 to monoclonal antibodies: biodistribution and imaging of athymic mice bearing human colon carcinoma xenografts. J Nucl Med. 1987; 28(5):861-70. View

HAND P, Calvo B, Milenic D, Yokota T, Finch M, Snoy P . Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant. Cancer Immunol Immunother. 1992; 35(3):165-74. PMC: 11038678. DOI: 10.1007/BF01756183. View

Pippin C, Parker T, McMurry T, Brechbiel M . Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates. Bioconjug Chem. 1992; 3(4):342-5. DOI: 10.1021/bc00016a014. View

Camera L, Kinuya S, Pai L, Garmestani K, Brechbiel M, Gansow O . Preclinical evaluation of 111In-labeled B3 monoclonal antibody: biodistribution and imaging studies in nude mice bearing human epidermoid carcinoma xenografts. Cancer Res. 1993; 53(12):2834-9. View

Salomon D, Brandt R, Ciardiello F, Normanno N . Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995; 19(3):183-232. DOI: 10.1016/1040-8428(94)00144-i. View

Kashmiri S, Schlom J, Calvo B, Shu L, Schott M, Milenic D . Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. Cancer Res. 1995; 55(23 Suppl):5957s-5967s. View

Wu C, Kobayashi H, Sun B, Yoo T, Paik C, Gansow O . Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-CyDTPA. Bioorg Med Chem. 1997; 5(10):1925-34. DOI: 10.1016/s0968-0896(97)00130-2. View

10.

van Gog F, Brakenhoff R, Stigter-van Walsum M, Snow G, Van Dongen G . Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer. Int J Cancer. 1998; 77(1):13-8. DOI: 10.1002/(sici)1097-0215(19980703)77:1<13::aid-ijc3>3.0.co;2-2. View

11.

LOWRY O, ROSEBROUGH N, FARR A, RANDALL R . Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193(1):265-75. View

12.

Harari P . Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer. 2004; 11(4):689-708. DOI: 10.1677/erc.1.00600. View

13.

Camp E, Summy J, Bauer T, Liu W, Gallick G, Ellis L . Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res. 2005; 11(1):397-405. View

14.

Navarro B, Casaco Parada A, Alvarez P, Leon A, Santana E, Bada A . Local and systemic toxicity of h-R3, an anti-epidermal growth factor receptor monoclonal antibody, labeled with 188osmiun after the intracerebral administration in rats. Exp Toxicol Pathol. 2005; 56(4-5):313-9. DOI: 10.1016/j.etp.2004.07.004. View

15.

Harding J, Burtness B . Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc). 2005; 41(2):107-27. DOI: 10.1358/dot.2005.41.2.882662. View

16.

Milenic D, Garmestani K, Brady E, Albert P, Ma D, Abdulla A . Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm. 2005; 20(5):557-68. DOI: 10.1089/cbr.2005.20.557. View

17.

Luo F, Yang Z, Dong H, Camuso A, McGlinchey K, Fager K . Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. Cancer Chemother Pharmacol. 2005; 56(5):455-64. DOI: 10.1007/s00280-005-1022-3. View

18.

Perk L, Visser G, Vosjan M, Stigter-van Walsum M, Tijink B, Leemans C . (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med. 2005; 46(11):1898-906. View

19.

Wild R, Fager K, Flefleh C, Kan D, Inigo I, Castaneda S . Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels. Mol Cancer Ther. 2006; 5(1):104-13. DOI: 10.1158/1535-7163.MCT-05-0259. View

20.

Wygoda Z, Kula D, Bierzynska-Macyszyn G, Larysz D, Jarzab M, Wlaszczuk P . Use of monoclonal anti-EGFR antibody in the radioimmunotherapy of malignant gliomas in the context of EGFR expression in grade III and IV tumors. Hybridoma (Larchmt). 2006; 25(3):125-32. DOI: 10.1089/hyb.2006.25.125. View